Tyra Biosciences 관리

관리 기준 확인 2/4

Tyra Biosciences CEO는 Todd Harris, Nov2018 에 임명되었습니다 의 임기는 6.25 년입니다. 총 연간 보상은 $ 4.63M, 13.2% 로 구성됩니다. 13.2% 급여 및 86.8% 보너스(회사 주식 및 옵션 포함). 는 $ 21.94M 가치에 해당하는 회사 주식의 2.56% 직접 소유합니다. 21.94M. 경영진과 이사회의 평균 재임 기간은 각각 3.2 년과 4.8 년입니다.

주요 정보

Todd Harris

최고 경영자

US$4.6m

총 보상

CEO 급여 비율	13.2%
CEO 임기	6yrs
CEO 소유권	2.6%
경영진 평균 재임 기간	3.2yrs
이사회 평균 재임 기간	4.8yrs

최근 관리 업데이트

Recent updates

Calculating The Intrinsic Value Of Tyra Biosciences, Inc. (NASDAQ:TYRA)

Oct 21

Tyra Biosciences: Upcoming FGFR3 Inhibitor Data Is A Major Inflection Point

Oct 21

Here's Why We're Not Too Worried About Tyra Biosciences' (NASDAQ:TYRA) Cash Burn Situation

Aug 29

Here's Why We're Not Too Worried About Tyra Biosciences' (NASDAQ:TYRA) Cash Burn Situation

Jul 21

Here's Why We're Not Too Worried About Tyra Biosciences' (NASDAQ:TYRA) Cash Burn Situation

Mar 31

Companies Like Tyra Biosciences (NASDAQ:TYRA) Are In A Position To Invest In Growth

Dec 15

CEO 보상 분석

Todd Harris 의 보수는 Tyra Biosciences 의 수익과 비교하여 어떻게 변경되었나요?
날짜	총 보상	급여	회사 수익
Sep 30 2024	n/a	n/a	-US$84m
Jun 30 2024	n/a	n/a	-US$81m
Mar 31 2024	n/a	n/a	-US$75m
Dec 31 2023	US$5m	US$608k	-US$69m
Sep 30 2023	n/a	n/a	-US$59m
Jun 30 2023	n/a	n/a	-US$51m
Mar 31 2023	n/a	n/a	-US$52m
Dec 31 2022	US$2m	US$581k	-US$55m
Sep 30 2022	n/a	n/a	-US$52m
Jun 30 2022	n/a	n/a	-US$46m
Mar 31 2022	n/a	n/a	-US$37m
Dec 31 2021	US$6m	US$443k	-US$26m
Sep 30 2021	n/a	n/a	-US$20m
Jun 30 2021	n/a	n/a	-US$16m
Mar 31 2021	n/a	n/a	-US$12m
Dec 31 2020	US$1m	US$350k	-US$9m

보상 대 시장: Todd 의 총 보상 ($USD 4.63M )은 US 시장( $USD 3.15M ).

보상과 수익: 회사가 수익성이 없는 동안 Todd 의 보상이 증가했습니다.

CEO

Todd Harris (45 yo)

6yrs

테뉴어

US$4,626,119

보상

Dr. Todd Harris, Ph D., co-founded Tyra Biosciences, Inc. and also has been its President, Chief Executive Officer and Secretary since November, 2018, Treasurer since February 2019 and Director since Augus...

리더십 팀

이름	위치	테뉴어	보상	소유권
Todd Harris	Co-Founder	6yrs	US$4.63m	2.56% $ 21.9m
Alan Fuhrman	Chief Financial Officer	1.8yrs	US$3.53m	0.024% $ 207.9k
Daniel Bensen	Co-Founder & COO	6yrs	US$2.43m	0.81% $ 6.9m
Robert Hudkins	Chief Technology Officer	3.8yrs	데이터 없음	데이터 없음
Ronald Swanson	Chief Scientific Officer	4.8yrs	US$2.53m	데이터 없음
Ali Fawaz	General Counsel	2.5yrs	US$2.76m	0.0032% $ 27.5k
Sarah Honig	Vice President of Corporate Development & Strategy	2.3yrs	데이터 없음	데이터 없음
Liz Pagano	Senior Vice President of Human Resources	less than a year	데이터 없음	데이터 없음
Piyush Patel	Chief Development Officer	3.8yrs	데이터 없음	데이터 없음
Douglas Warner	Chief Medical Officer	less than a year	데이터 없음	데이터 없음
Amy Conrad	Investor Contact	no data	데이터 없음	데이터 없음

3.2yrs

평균 재임 기간

58yo

평균 연령

경험이 풍부한 관리: TYRA 의 관리팀은 경험 ( 3.2 년 평균 재직 기간)으로 간주됩니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Todd Harris	Co-Founder	6.3yrs	US$4.63m	2.56% $ 21.9m
Robert J. More	Independent Director	6yrs	US$231.55k	0% $ 0
Peter Smith	Scientific Advisor	no data	데이터 없음	데이터 없음
Gilla Kaplan	Independent Director	5.7yrs	US$195.05k	0.17% $ 1.5m
Nina Kjellson	Independent Director	4.8yrs	US$196.05k	0% $ 0
Brian Schwartz	Scientific Advisor	no data	데이터 없음	데이터 없음
William Hahn	Scientific Advisor	no data	데이터 없음	데이터 없음
Jeffrey Hager	Scientific Advisor	no data	데이터 없음	데이터 없음
Rehan Verjee	Independent Director	3.4yrs	US$201.05k	0% $ 0
Melissa McCracken	Independent Director	3.7yrs	데이터 없음	데이터 없음
Jake Simson	Independent Director	4.8yrs	US$200.05k	0% $ 0
Jason Sheltzer	Scientific Advisor	no data	데이터 없음	데이터 없음

4.8yrs

평균 재임 기간

49yo

평균 연령

경험이 풍부한 이사회: TYRA 의 이사회는 경험(평균 재직 기간 4.8 년)으로 간주됩니다.

Tyra Biosciences 관리

관리 기준 확인 2/4

주요 정보

최근 관리 업데이트

Chief Financial Officer recently bought US$152k worth of stock

Co-Founder notifies of intention to sell stock

Co-Founder notifies of intention to sell stock

Insufficient new directors

Tyra Biosciences, Inc. Announces Board Changes

Tyra Biosciences, Inc., Annual General Meeting, May 29, 2024

Recent updates

Chief Financial Officer recently bought US$152k worth of stock

Now 22% undervalued after recent price drop

Tyra Biosciences Receives IND Clearance from FDA to Proceed with Phase 2 Study of TYRA-300 in Pediatric Achondroplasia (BEACH301)

Tyra Biosciences Reports Interim Clinical Proof-Of-Concept Data for TYRA-300, an Investigational Oral FGFR3-Selective Inhibitor, in Phase 1/2 SURF301 Study in Patients with Metastatic Urothelial Cancer (mUC)

Calculating The Intrinsic Value Of Tyra Biosciences, Inc. (NASDAQ:TYRA)

Tyra Biosciences: Upcoming FGFR3 Inhibitor Data Is A Major Inflection Point

New major risk - Revenue and earnings growth

Co-Founder notifies of intention to sell stock

Price target increased by 8.2% to US$28.50

Co-Founder notifies of intention to sell stock

Price target increased by 9.8% to US$27.67

Now 20% undervalued

Here's Why We're Not Too Worried About Tyra Biosciences' (NASDAQ:TYRA) Cash Burn Situation

Now 21% overvalued after recent price rise

Lots Of Bullish Signals, But No Revenue Or Earnings From Tyra Biosciences

Now 22% overvalued after recent price rise

A Look At The Intrinsic Value Of Tyra Biosciences, Inc. (NASDAQ:TYRA)

Price target increased by 7.7% to US$25.20

Tyra Biosciences, Inc.(NasdaqGS:TYRA) dropped from Russell 3000E Value Index

Insufficient new directors

Now 29% overvalued

We're Not Very Worried About Tyra Biosciences' (NASDAQ:TYRA) Cash Burn Rate

New major risk - Revenue and earnings growth

Tyra Biosciences, Inc. Announces Board Changes

Tyra Biosciences, Inc., Annual General Meeting, May 29, 2024

Insufficient new directors

New major risk - Revenue and earnings growth

Price target increased by 9.0% to US$24.20

Co-Founder notifies of intention to sell stock

New major risk - Revenue and earnings growth

Tyra Biosciences, Inc. announced that it expects to receive $200 million in funding from RA Capital Management, L.P., Boxer Capital LLC, BVF Partners L.P., Nextech Invest Ltd., OrbiMed Advisors LLC, 5AM Venture Management, LLC

New minor risk - Share price stability

We're Not Very Worried About Tyra Biosciences' (NASDAQ:TYRA) Cash Burn Rate

Tyra Biosciences, Inc. Doses First Patient with TYRA-200 and Provides Positive Updates on TYRA-300

Price target decreased by 9.0% to US$22.20

We Think Tyra Biosciences (NASDAQ:TYRA) Can Afford To Drive Business Growth

Price target increased by 8.4% to US$24.40

Tyra Biosciences Announces Fda Orphan Drug Designation for Tyra-300 for the Treatment of Achondroplasia

Co-Founder exercised options and sold US$286k worth of stock

Tyra Biosciences (NASDAQ:TYRA) Is In A Good Position To Deliver On Growth Plans

Co-Founder & COO exercised options and sold US$350k worth of stock

Tyra Biosciences (NASDAQ:TYRA) Is In A Good Position To Deliver On Growth Plans

Price target decreased by 8.3% to US$19.25

Tyra Biosciences, Inc. Initiates SURF301 Phase 1/2 Clinical Study and Doses First Patient with TYRA-300

High number of new directors

Tyra Biosciences (NASDAQ:TYRA) Is In A Good Position To Deliver On Growth Plans

Price target decreased to US$20.00

Tyra Biosciences Announces Chief Financial Officer Changes

Tyra Biosciences, Inc. Announces Appointment of Ali Fawaz as General Counsel and Secretary

Tyra Biosciences GAAP EPS of -$0.36

Here's Why We're Not Too Worried About Tyra Biosciences' (NASDAQ:TYRA) Cash Burn Situation

Tyra Biosciences, Inc.(NasdaqGS:TYRA) dropped from Russell 2000 Growth Index

High number of new directors

Here's Why We're Not Too Worried About Tyra Biosciences' (NASDAQ:TYRA) Cash Burn Situation

High number of new directors

Companies Like Tyra Biosciences (NASDAQ:TYRA) Are In A Position To Invest In Growth

Tyra Biosciences, Inc. has completed an IPO in the amount of $172.8 million.

CEO 보상 분석

CEO

테뉴어

보상

리더십 팀

평균 재임 기간

평균 연령

이사회 구성원

평균 재임 기간

평균 연령